Reval has released version 4.2 of HedgeRxTM. Its features include derivative instruments, an expanded range of independent valuations and the IAS 39 Doctor, a documentation tool for compliance with derivative reporting requirements under international financial reporting standards (IFRS). HedgeRx offers new coverage and independent valuations of instruments ranging from Mexican TIEE to Singapore dollar interest rate swaps. “We’re already live with IAS 39 with European clients and continue to add features at the advice of the big four accounting firms and their clients” says Philip Pettinato, COO of Reval. “Our IAS 39 Doctor is another example of how we make it easier to understand and comply with new regulatory requirements.” The IAS 39 Doctor allows companies to understand the accounting effect of hedging strategies and provides the at-inception documentation required under the standard.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.